Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
AssigneeAlderbio Holdings LLC
InventorsLeon Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Olson, Ben Dutzar, John Latham, Brian Kovacevich, Jeffrey T. L. Smith, Mark Litton, Randall Schatzman
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of anti-IL-6 antibodies or antibody fragments containing a specific epitopic specificity to treat conditions involving elevated Il-6. In some embodiments the anti-IL-6 antibodies contain specific CDRs.
Claims21
A method of treating a disease or condition associated with elevated human interleukin-6 (IL-6), comprising administering a therapeutically effective amount of an anti-IL-6 antibody or antibody fragment to a subject in need thereof, wherein the antibody or antibody fragment comprises:
- a variable light chain polypeptide comprising the CDRs of SEQ ID NOs:4, 5 and 6 and possessing at least 90% identity to the variable light chain polypeptide of SEQ ID NO:709, and
- a variable heavy chain polypeptide comprising the CDRs of SEQ ID NOs:7, 8 or 120, and 9 and possessing at least 90% identity to the variable heavy chain polypeptide of SEQ ID NO:657, and;
- wherein the antibody or antibody fragment specifically binds to IL-6 and antagonizes one or more activities associated with IL-6 and specifically binds to the same epitope(s) on IL-6 as an anti-IL-6 antibody comprising the variable light chain polypeptide in of SEQ ID NO:709 and the variable heavy chain polypeptide of SEQ ID NO:657.
A method of treating a disease or condition associated with elevated human interleukin-6 (IL-6), comprising administering a therapeutically effective amount of an anti-IL-6 antibody or antibody fragment to a subject in need thereof, wherein the antibody or antibody fragment comprises the variable light chain and variable heavy chain polypeptides of SEQ ID NOs:709 and 657, respectively.
A method of treating a disease or condition associated with elevated human interleukin-6 (IL-6), comprising administering a therapeutically effective amount of an anti-IL-6 antibody or antibody fragment to a subject in need thereof, wherein the antibody or antibody fragment comprises:
- (a) variable light and variable heavy chain polypeptides comprising:
- SEQ ID NO:709 and SEQ ID NO:657;
- SEQ ID NO:702 and SEQ ID NO:704;
- SEQ ID NO:706 and SEQ ID NO:708;
- SEQ ID NO:20 and SEQ ID NO:19;
- or SEQ ID NO:2 and SEQ ID NO:3;
- or
- (b) a polypeptide having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to any of the polypeptides and comprising the same CDRs of the corresponding polypeptide of (a);
- wherein the antibody or antibody fragment specifically binds to IL-6 and antagonizes one or more activities associated with IL-6 and specifically binds to the same epitope(s) on human IL-6 as an anti-IL-6 antibody comprising the variable light chain polypeptide in of SEQ ID NO:709 and the variable heavy chain polypeptide of SEQ ID NO:657.
Dependencies are inferred from the claim text.